GlassScriptPhysician profile
Katherine L Stone
NPI 1538208517
$4,457.51
in general payments reported to CMS, 2019-2025
15 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,601 · 2023: $520 · 2024: $746 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,819.60 | 2022-2025 | Cardiomems |
| Actelion Pharmaceuticals US, INC. | $360.09 | 2023-2024 | Opsumit, Uptravi |
| Abiomed | $186.52 | 2022-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.73 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $162.00 | 2023-2025 | Winrevair, Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $116.37 | 2023-2025 | |
| Scpharmaceuticals INC. | $114.66 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $106.42 | 2022-2025 | |
| Novo Nordisk INC | $83.94 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $82.55 | 2024-2025 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $79.31 | 2022-2025 | Camzyos, Eliquis |
| United Therapeutics Corporation | $78.01 | 2023-2025 | Tyvaso, Tyvaso, Remodulin |
| Pfizer INC. | $46.72 | 2024 | |
| Amgen INC. | $20.46 | 2024 | Repatha |
| Bridgebio Pharma, INC. | $20.13 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.